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S U M M A R Y
Objective: Some medical conditions constitute important risk factors for the development of invasive
pneumococcal diseases in children and adolescents aged from 5 to 19 years. Conjugate vaccines have
potential efﬁcacy in this scenario, but are not available in many Latin American public healthcare
systems for this age group. This study aimed to estimate the preventable fraction of invasive
pneumococcal diseases among individuals aged from 5 to 19 years with associated risk factors for its
development.
Methods: Data regarding the Latin America population, risk factors prevalence and conjugate vaccines
efﬁcacy were obtained from the literature.
Results: Total population at risk ranged from 17.3 to 64.6 million of individuals and asthma was the most
impacting risk factor. According to SIREVA, PCV13 provided a 62.9% serotypes coverage in individuals
from 5 to 29 years in 2012, potentially increasing the covered population from [8,338,457-31,057,620]
with PCV10 to [10,906,356-40,622,078] with PCV13. To date, according to available efﬁcacy data, the
hypothetically immunized population ranged from 11.4 to 42.4 million, representing 7.0% to 26.0% of the
total population in this age group.
Conclusions: Vaccination in risk groups should be encouraged, as it potentially contributes to the
reduction in the number of cases of invasive pneumococcal disease.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Despite the current scenario of population aging and the
predominance of chronic degenerative diseases as the main cause
of death, invasive pneumococcal diseases (IPD) (meningitis,
bacterial pneumonia and bacteremia/sepsis) still constitute a* Corresponding author. Faculdade de Medicina da Universidade Metropolitana
de Santos Campus Bandeirante I, Rua da Constituic¸a˜o, n8 374 Vila Nova – Santos –
SP, CEP 11015-470. Tel.: +13 3226-3400; fax: +13 3235-2990.
E-mail address: luizahfc@terra.com.br (L.H. Falleiros-Arlant).
http://dx.doi.org/10.1016/j.ijid.2015.06.016
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).major cause of mortality in Latin America (LA), especially among
children and elderly people.1
Streptococcus pneumoniae is the most prevalent etiologic agent
associated with pneumonia cases in LA, accounting for 11.08% of
all disease causes.2 The average incidence of pneumococcal
pneumonia is estimated at 918 cases per 100,000 child-years in
the age group of up to ﬁve years.2 Pneumonia associated mortality
for any etiologic agent in adults over 50 years is estimated at
17.7%, with 20-60% of cases related to S. pneumoniae.3 In addition,
bacteremia may occur in up to 30% of patients with pneumococcal
pneumonia, with 20% mortality in children, reaching up to 60% in
the elderly.4ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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estimated that 6.0% of all meningitis are due to pneumococcus. The
incidence in this context is an average of 8.34/100,000 in children
aged 0-23 months, and 4.62/100,000 in the age group of up to ﬁve
years. The mortality rate is high among the elderly reaching 80%
and ranges from 1.8% to 14.9% among children aged up to
59 months.4,5
Serotypes 1, 3, 5, 6A/B, 7F, 9 V, 14, 18C, 19A/F, and 23F are the
most frequently found in LA. These serotypes are covered by both
conjugate vaccines (PCV7 contains 4, 6B, 9 V, 14, 18C, 19F and 23F
serotypes; PCV10 also covers serotypes 1, 5 and 7F in addition to
PCV7; and PCV13 contains serotypes 1, 3, 5, 6A, 7F and 19A in
addition to PCV7) and the polysaccharide vaccine PPSV23
(serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9 V, 10A, 11A, 12F, 14, 15B,
17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F). Thus, despite the high
incidence of IPD, available vaccines show potential efﬁcacy in this
scenario, setting up a preventable health problem in these
countries.
It is known that the incidence of IPD in children and adolescents
aged 6 to 17 years is low.6 Nevertheless, the disease estimation in
LA is incipient in this age range due the lack of active surveillance
in that particular group. In addition, some medical conditions
constitute important risk factors for this age group, such as renal
failure, liver failure, chronic lung disease (including asthma),
diabetes mellitus, asplenia, cancer, HIV and other diseases.7,8
Despite this, little research has been carried out in LA and
speciﬁcally in subjects aged up to 19 years in order to describe the
incidence, prevalence, morbidity and additional risk factors for
these subgroups. However, research performed in other ﬁelds has
shown that PD incidence in these individuals is actually higher
when compared to those without such conditions.9 Examples
include patients with diabetes, cancer, chronic pulmonary and
cardiac diseases having IPD incidence estimated at 34.9 cases per
100,000 people. By comparison, IPD incidence for individuals with
same age, but no risk factors was evaluated at 8.8/100,000.9
In certain surveys conducted in the United States (US), IPD
incidence ranged from 21.1 to 23.0/100,000 in adults with
moderate to severe asthma.10,11 However, in adults without
asthma, incidence was estimated at 8.8/100,000.11 When asth-
matic individuals aged 2-49 years were considered, IPD incidence
was 42/100,000.11 This suggests that IPD incidence may be higher
among asthmatic children and adolescents when compared to
adults with the same condition. Regarding IPD prevalence, the
magnitude varied from 17.1 to 17.7% in asthmatic children and
adolescents aged 5-17 years vs. 5.5 to 8.1% among subjects with
the same age, but without asthma.10
Another commonly vulnerable subgroup to pneumococcal
infections is end-stage renal disease. Among these patients, IPDs
are the second cause of death and the leading cause of hospitaliza-
tion. This situation takes place, in part, by uremia related to decrease
of immune function, and also by exposure to infection through the
dialysis catheter. The most common infections among them are
urinary tract infections, sepsis and pneumonia.12
Subjects with any immunosuppressive condition are also
particularly vulnerable to S. pneumoniae, including, therefore,
positive HIV patients. IPD incidence in HIV positive individuals is
estimated at 246/100,000 for those aged 15-44 years and is still
higher among patients not using antiretroviral therapy (281/
100,000) and those with severe immunosuppression (563/
100,000).13
Sickle cell disease is also considered a risk factor for IPD
development, besides presenting a worse prognosis when com-
pared to individuals without the disease. In a US study with
children and adolescents under 18 years old with sickle cell
disease, they were more likely to be hospitalized (84%-92% vs. 31%-
56%) and had higher risk to die (6%-17% vs. 1%-2%) when comparedto children and adolescents with IPD, but without this additional
risk factor.14
Van Hoek and colleagues reported that among children aged 2 to
15 years the presence of one or more risk factors is associated with a
11.7 times greater probability of developing IPD.15 Among risk
factors, diabetes mellitus incidence in adolescents is an important
condition which implies a higher risk for developing bacteremia,
invasive forms, and higher mortality. However, studies deﬁning the
risk magnitude only in individuals with diabetes are scarce.16
Patients with risk factors mentioned above seem to beneﬁt from
vaccination against pneumococcus. Immunization of people highly
vulnerable to IPD development is not performed in many LA
countries. Such intervention represents an important strategy for
reducing morbidity and mortality. Thus, this study aims to estimate
the preventable fraction of IPD among children and adolescents from
5 to 19 years of age with a risk factor for their development.
2. Material and methods
The total population in LA was estimated from data provided by
the Latin American and Caribbean Demographic Center (CELADE)
for the year 2014.17 This included the following countries:
Argentina, Plurinational State of Bolivia, Brazil, Chile, Colombia,
Costa Rica, Cuba, Ecuador, El Salvador, Guatemala, Haiti, Honduras,
Mexico, Nicaragua, Panama, Paraguay, Peru, Dominican Republic,
Uruguay and Bolivarian Republic of Venezuela.
Prevalence data (in percentage) for speciﬁc risk population was
searched in the literature in order to calculate the preventable
fraction of IPD in the Latin American population. We sought studies
that evaluated the prevalence of pneumococcal disease in patients
in high-risk groups. The electronic searches were conducted until
July 2014 in the databases MEDLINE via PubMed and LILACS using
the following terms combined in a variety of strategies: anatomic
asplenia, functional asplenia, kidney diseases, HIV infection,
asthma, diabetes mellitus, children and Latin America. Search
engines additionally included Google1. Electronic searches were
supplemented by manual searches of bibliographic references.
Information extracted from abstracts was not considered.
Thus, data on the prevalence of asthma, renal disease (dialysis
patients), diabetes mellitus, sickle cell disease and HIV were
applied to the total population in LA, and thus the risk population
was obtained. When prevalence data were not available for the LA,
information from other domains was used.
The vaccine efﬁcacy in speciﬁc risk population for each
subgroup was used in order to calculate the preventable fraction.
Calculations were performed by estimating the use of PCV13
conjugate vaccine, exclusively. Searches were conducted in the
databases mentioned above, in the same period, using the
following terms: pneumococcal vaccines, children and the diseases
mentioned above. Currently, there is no data on PCV13 efﬁcacy in
pediatric patients at high-risk in published papers. Therefore, data
regarding other conjugate vaccines was used. This scenario
considered that all vulnerable population had access to immuni-
zation. The impact of herd immunity was not considered. Table S1
provides information of all articles used as a data source.
3. Results
CELADE stratiﬁes individuals into ﬁve-year age groups, and
therefore the analysis was performed considering the maximum
age of 19 years. According to CELADE, 215,197,435 people are aged
between 0 and 19 years in LA and 162,950,134 constitute the age
group of 5-19 years.
Table 1 shows the prevalence of asthma, renal disease, diabetes,
sickle cell disease and HIV in four different age groups (0-4, 5-9,
10-14, and 15-19 years old).18–22 In this analysis, subjects aged
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L.H. Falleiros-Arlant et al. / International Journal of Infectious Diseases 38 (2015) 1–6 35-19 years were considered. Risk populations according to
prevalence rates are also available. Due the lack of prevalence
information for certain age groups, the closer age available was
used and generalized.
The total population at risk within the age group of interest
ranged from 17.3 to 64.6 million, according to available data.
Asthma was the risk factor with the greatest impact, with
14.6 million children and adolescents susceptible to IPD. Among
the evaluated factors, sickle cell disease and renal disease
presented the lowest impact on the total number of individuals
at risk, with 1,385-418,782 (according to the prevalence data
used), and 81,475 susceptible, respectively.
Table 2 shows the number of subjects potentially covered by
each conjugate vaccine. According to the Regional Vaccine System
(SIREVA) 201223 published in 2013, considering prevalent
serotypes in LA and serotypes contained in conjugate vaccines,
PCV10 offers a 48.1% coverage for individuals aged 5 to 29 years in
LA and PCV13, a 62.9% coverage. Thus, potentially covered
population increased from 8,338,457-31,057,620 patients with
the use of PCV10 to 10,906,356-40,622,078 with PCV13.
The number of subjects possibly immunized after PCV13
application using currently available efﬁcacy data is presented in
Table 3.24,25 There is no data on PCV13 efﬁcacy in children at high-
risk in published papers, therefore, in children with sickle cell
disease, efﬁcacy of PCV7 was used. Moreover, the others groups
were calculated by extrapolating data from the efﬁcacy of PCV9 in
HIV-infected children. In this scenario, the hypothetical immu-
nized population ranged from 11.4 to 42.4 million, approximately.
Individuals with asthma were the majority and accounted for
77.4% to 84.5% of individuals who would beneﬁt from vaccination.
4. Discussion
4.1. Generalization of the prevalence estimates
To calculate the population who would be immunized for IPD,
data on the prevalence of some risk factors, as well as conjugate
vaccines efﬁcacy, were generalized. These extrapolations were
performed from a restricted to a wider domain, as well as between
different age groups. The risk factors used in this study are just
some of the factors associated with the development of
pneumococcal disease. However, they were used because they
were the available data at the time when the search was conducted
in the literature.
Regarding diabetes mellitus and HIV prevalence, data related to
the population in LA were applied for all age groups, as the original
information source did not provide it stratiﬁed by age. Also, type
2 diabetes mellitus data were used, speciﬁcally. Data found for type
1 diabetes mellitus was incidence, and was not considered.
Regarding HIV, possibly the prevalence is higher among adoles-
cents due to sexual transmission and drug use, compared to
children, where transmission takes place vertically. Thus, the total
population at risk due to HIV may have been overestimated among
children 5-9 years. The same phenomenon may have occurred in
type 2 diabetes mellitus, with the prevalence overestimated
among children.
Murray and colleagues estimated that people living with HIV in
LA are 18.7% smaller than previously estimated.26 In this scenario,
the number of at-risk individuals could range from 529,914 to
794,871.
In asthma, the data comes from the estimates obtained by the
International Study of Asthma and Allergies in Childhood (ISAAC)
Phase Three, an international multi-center cross-sectional study
involving two age groups of school children, 13-14 year olds
(adolescents) and 6-7 year olds (children).18 Being a population-
based study, generalizability of these data to a wider ﬁeld is
Table 2
Population potentially covered by each conjugate vaccine available in Latin America
Potentially covered population with the use of conjugate vaccines*
Population at risk (5 – 19 years) PCV10 (48.1% coverage) PCV13 (62.9% coverage)
Total population 17,340,529 – 64,586,955 8,338,457 – 31,057,620 10,906,356 – 40,622,078
Asthma 14,650,466 – 50,072,986 7,044,900 – 24,078,358 9,214,436 – 31,493,492
Renal diseases (dialysis) 81,475 39,178 51,244
Diabetes type 2 1,955,402 – 13,036,011 940,285 – 6,268,564 1,229,854 – 8,199,022
Sickle cell disease 1,385 – 418,782 666 – 201,378 871 – 263,394
HIV 651,801 – 977,701 313,428 – 470,142 409,951 – 614,927
Note: potential coverage data were obtained by serotypes prevalence in Latin America according to SIREVA 2012. PCV10 is not indicated for the age group analyzed,
calculation made only for comparison.
* Coverage in the age group 5-29 years. PCV7 = conjugate vaccine with 7 serotypes. PCV10 = conjugate vaccine with 10 serotypes. PCV 13 = conjugate vaccine with
13 serotypes.
L.H. Falleiros-Arlant et al. / International Journal of Infectious Diseases 38 (2015) 1–64plausible. In addition, some of the age groups were not covered.
Thus, prevalence rates for these groups were repeated from
available data. Due to these generalizations in prevalence data, the
population at risk, as well as the immunized population, can be
either underestimated or overestimated.
Prevalence rates for chronic renal disease and sickle cell disease
in LA were not found. Therefore, data were generalized from
Brazilian studies, each one with its peculiarities.
Data of children and adolescents on dialysis were obtained from
the Brazilian census of chronic dialysis for children and adolescents
up to 12 years.19 This estimate was used in all age groups due to
lack of stratiﬁcation of age on the source of information. Even so,
signiﬁcant ﬂuctuations of this prevalence by age group are not
expected.
Prevalence data for sickle cell disease was also originated from
Brazilian population. Speciﬁc sickle cell disease information was
used.21 Since this is a genetic disease, variation among age groups
is not ﬂoating. Nevertheless, the wide prevalence range is due to
regional variation in Brazil.
It should be considered that in healthy children the risk of IPD
decreases with age, but in those at high-risk, it continues at the
same pace.8
4.2. Generalization of conjugate vaccine efﬁcacy
Available literature data on PCV13 efﬁcacy are restricted to
children under ﬁve years and healthy adults over 50 years and with
no immunosuppressive risk factors. Efﬁcacy data with PCV10 and
13 are not available because they were not published. Previous
works were made with PCV7. Thus, PCV7 data was used for
patients with sickle cell disease and PCV9 for HIV-positive
patients.24,25 Due to lack of information on vaccine efﬁcacy for
other risk categories, these groups were determined using the
vaccine efﬁcacy in HIV patients. This strategy was used becauseTable 3
Population at risk for pneumococcal diseases that would beneﬁt from PCV13 applicati
Population at risk
(5 – 19 years)
Vaccine efﬁca
(PCV)
Total population 17,340,529 – 64,586,955 – 
Asthma 14,650,466 – 50,072,986 65.0 l
Renal diseases (dialysis) 81,475 65.0 l
Diabetes type 2 1,955,402 – 13,036,011 65.0 l
Sickle cell disease 1,385 – 418,782 81.4 m
HIV 651,801 – 977,701 65.0 l
l Extrapolated data from the efﬁcacy of PCV9 in HIV-infected children.
m Efﬁcacy of PCV7 evaluated in children with sickle cell disease.
IPD = invasive pneumococcal diseases. PCV = pneumococcal conjugate vaccine.HIV-patient data represents the lowest estimated vaccine efﬁcacy
available in the literature, in order to avoid an overestimated
immunized population in these risk groups.
4.3. Beneﬁts for the population likely to be immunized and for general
population
Population that would beneﬁt from conjugate vaccination
considering PCV7/9 ranged from 11.4 to 42.4 million, accounting
for 7.0-26.0% of the general population at this age group. This
information is probably underestimated, as only some risk
situations were evaluated among all the existing risk conditions
for IPD. Nevertheless, immunization provides a large impact on
that particular population. In addition to preventing IPD,
immunization also prevents minor IPD as sinusitis and otitis,
among others.27
4.4. Incorporation of vaccines for pneumococcal disease in different
Latin American countries
PCV7 was licensed in 2000 in order to provide protection
against seven of the most common pneumococcal serotypes. In
2006, the World Health Organization (WHO) recommended the
vaccine inclusion in all routine immunization programs, especially
in countries with a high IPD burden, deﬁned as >10% pneumonia
attributed deaths in children aged <5 years or pneumonia
mortality rate >50 deaths per 1,000 live births among children
aged <5 years. In early 2010, new formulations with protection
against 10 and 13 serotypes have become available for use.28
By 2014, the following countries in LA introduced the PCV in
their national immunization programs: Costa Rica (2009); Mexico
(2006), Uruguay (2007); Peru (2009); Brazil (2010), Ecuador
(2010), El Salvador (2010), Panama (2010), Nicaragua (2011); Chile
(2011), Colombia (2010), Honduras (2011), Argentina (2012),on in Latin America
cy % Potentially beneﬁted individuals
with lower risk of developing IPD
Reference
11,358,266 – 42,371,042 –
9,596,055 – 32,797,806 Klugman 200324
53,366 Klugman 200324
1,280,788 – 8,538,587 Klugman 200324
1,127 – 340,888 Adamkiewicz 200825
426,929 – 640,394 Klugman 200324
L.H. Falleiros-Arlant et al. / International Journal of Infectious Diseases 38 (2015) 1–6 5Guatemala (2012), Paraguay (2013), Dominican Republic (2013),
Venezuela (2014) and Bolivia (2014).29–33
4.5. Vaccines coverage for pneumococcal disease
The immunization of high-risk population against IPD aged
between 2 and 65 years has been conducted in several countries
with the administration of PPSV23. However, immunocompro-
mised patients do not present good response to polysaccharide
vaccines, being conjugate vaccines the best option for this group.34
PCV10 contains the seven PCV7 serotypes plus three additional
serotypes. However it is not indicated for subjects aged more than
5 years. PCV13 provides a wider coverage, since it includes six
additional serotypes versus PCV7. According to SIREVA 2012,
PCV10 presents 48.1% of coverage considering serotypes present in
LA for individuals aged from 5 to 29 years. Therefore, considering
the entire population at risk aged 5 to 19 years presented in
Table 1, from 8.3 to 31.1 million people would be covered with this
vaccine administration. Along those same lines, PCV13 has a
greater coverage (62.9%) immunizing from 10.9 to 40.6 million of
individuals. PCV13 is the only conjugate vaccine that includes
serotypes 3, 6A and 19A, and in most countries this vaccine
replaced the PCV7/10. Although not all of these serotypes are
known to cause invasive disease exclusively, serotypes contained
in PCV10 and the additional serotypes contained in PVC13 are
major causes of IPD and acute otitis media.
However, it should be noted that Table 2 presents the population
potentially covered by each conjugate vaccine in LA. This
information does not take into account, the vaccine efﬁcacy, among
covered serotypes, in preventing cases. Thus, Table 2 considers a
supposed 100% efﬁcacy for serotypes covered by each vaccine.
The broadest coverage provided by PCV13 means, in practical
terms, higher probability to prevent IPD cases, favoring not only
children and adolescents with risk factors, but the entire
population. The wider coverage of PCV13 reafﬁrms its superiority
versus conjugate vaccines with less serotypes. Nevertheless,
vaccine efﬁcacy especially in patients with risk factors for IPD is
not ensured. It is known that patients with diseases and risk factors
have a lower response to vaccination.24,25 Because of this, Table 3
presents efﬁcacy data for risk groups obtained in clinical trials. This
data indicates that, despite the lower efﬁcacy for this particular
group, a large population could be beneﬁted.
On the other hand, despite PCV13’s protection against IPD, some
studies indicate that IPD incidence by serotypes not included in the
vaccine has increased up to 140%.35,36 Thus, PCV13 should be seen
only as part of the solution for IPD in LA. In addition, the combination
of several risk factors is extremely important, and is present in many
patients with an even greater risk of pneumococcal infection.
The introduction of PCV13 as well as PPSV23 was recently
recommended by ACIP in population aged 6 to 18 years under such
conditions. This recommendation calls for the use of vaccines in
children and adolescents in some situations of higher risk for
invasive pneumococcal infections such as cerebrospinal ﬂuid leak
and cochlear implants, hemoglobinopathies, congenital or acquired
immunodeﬁciency, cancer, renal failure, and others.37 Currently,
the minimum interval for vaccination with PPSV23 after PCV13 use
is 8 weeks in subjects aged up to 65 years. Although PCV13 is
approved in many Latin American countries for individuals above
50 years of age, the ofﬁcial schedule recommendations only include
the age group above 65 years (in Brazil, over 60 years old). In such
conditions, the recommended vaccine should be PCV13. If the
patient has more than 65 years, a PPSV23 dose is recommended
with a minimum interval of 6-12 months after PCV13. In adults
over 65 years and PCV13-naive previously vaccinated with PPSV23,
a dose of PCV13 should be administered at least 1 year after the
latest PPSV23 vaccine. If a new dose of PPSV23 is indicated (inindividuals with some persistent risk factors), the interval must
be of at least 5 years since the last dose of PPSV23. This
recommendation will be reviewed in 2018 by the ACIP and CDC.38
4.6. Strengths and limitations
This study should be interpreted taking into account that the
availability of different data in literature contributes to a possible
under/overestimated number of susceptible individuals. Also,
there are several factors that may increase a child’s risk of IPD,
but it was not considered a possible association of two or more
factors, in which an individual could be included in more than one
group evaluated. Thus, the number of children or adolescents at
risk may be overestimated.
The demonstrated calculations do not consider that in some LA
countries vaccination of children up to two years is occurring
systematically, such as Argentina, Brazil, Uruguay and others. Thus,
results were overestimated especially among those countries.
However, a positive highlight is the use of the entire population
in LA, because these countries present comparable epidemiological
proﬁles regarding IPD incidence and prevalence. The target
population of this research is also a positive highlight (children
and adolescents with risk factors to develop IPD), considering they
are frequently vulnerable and often neglected in studies of IPD
prevention in LA.
5. Conclusion
Despite the stated limitations, vaccinating against IPD in
children and adolescents with risk factors against IPD represents
a major opportunity in this speciﬁc population. Public policies
favoring IPD vaccination should be encouraged in LA by
international protocols. This incentive would decrease mortality
in adolescents and especially among children, supporting the
reduction of child mortality - one of the millennium goals proposed
by WHO.39
Supporting Information: Table S1. Data used in the calculation of
prevalence of IPD in different high-risk groups and vaccine efﬁcacy
in these groups.
Conﬂict of interest statement: Luiza Helena Falleiros Arlant has
received travel or honorarium support for participation as a
speaker, in external expert committees or advisory boards for MSD,
Sanoﬁ Pasteur, Pﬁzer, GlaxoSmithKline and Novartis. Currently,
she is the co-coordinator of GREEN (Regional Study Group
Pneumococcal Disease).
Maria Luisa Avila-Aguero has worked as a speaker for Pﬁzer,
Sanoﬁ Pasteur, MSD and Novartis. She was member of the Advisory
Board of GlaxoSmithKline, Pﬁzer, and MSD. Currently, she is the
coordinator of GREEN (Regional Study Group Pneumococcal
Disease) which is part of SLIPE (Latin American Society for
Pediatric Infectious Diseases).
Marı´a Catalina Pı´rez has received travel or honorarium support
for participation in external expert committees or advisory boards
for Merck Sharp & Dohme, Sanoﬁ Pasteur, Pﬁzer, GlaxoSmithKline,
Novartis and Instituto Sabin, has received honorarium support for
consulting for Amsud Pasteur Foundation/Banco interamericano
de Desarrollo and has received speaker honoraria for presentations
for Pﬁzer.
Jose Brea has received speaker honoraria for presentations for
Pﬁzer, Sanoﬁ-Pasteur, GSK, Novartis, MSD and participaded in
advisory boards for Pﬁzer, Sanoﬁ-Pasteur, GSK.
Cristina Marin˜o has received travel or honorarium support for
participation in external expert committees or advisory boards for
Merck Sharp & Dohme, Sanoﬁ Pasteur, Pﬁzer, GlaxoSmithKline and
Novartis. The other authors have declared that no competing
interests exist.
L.H. Falleiros-Arlant et al. / International Journal of Infectious Diseases 38 (2015) 1–66Acknowledgments
We thank Laura Haas (SENSE Company, Brazil) for editorial
support in developing drafts of this manuscript. The authors were
responsible for critical revisions of the manuscript for important
intellectual content.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.ijid.2015.
06.016.
References
1. Valenzuela MT, O’Loughlin R, De La Hoz F, Gomez E, Constenla D, Sinha A, et al.
The burden of pneumococcal disease among Latin American and Caribbean
children: review of the evidence. Rev Panam Salud Publica 2009;25(3):270–9.
2. Gentile A, Bardach A, Ciapponi A, Garcia-Marti S, Aruj P, Glujovsky D, et al.
Epidemiology of community-acquired pneumonia in children of Latin America
and the Caribbean: a systematic review and meta-analysis. Int J Infect Dis
2012;16(1):e5–15.
3. Buzzo AR, Roberts C, Mollinedo LG, Quevedo JM, Casas GL, Soldevilla JM.
Morbidity and mortality of pneumonia in adults in six Latin American countries.
Int J Infect Dis 2013;17(9):e673–7.
4. Centers for Disease Control and Prevention (CDC). Pneumococcal disease. In:
Atkinson W, Hamborsky J, Wolfe S, editors. Epidemiology and Prevention of
Vaccine-Preventable Diseases.. 12th ed, 2012. p. 233–48.
5. Ciapponi A, Elorriaga N, Rojas JI, Romano M, Martı´ SG, Bardach A, et al.
Epidemiology of pediatric pneumococcal meningitis bacteremia in Latin Amer-
ica and the Caribbean: a systematic review meta-analysis. Pediatr Infect Dis J
2014;33(9):971–8.
6. Mitchell R, Tru¨ck J, Pollard AJ. Use of the 13-valent pneumococcal conjugate
vaccine in children and adolescents aged 6-17 years. Expert Opin Biol Ther
2013;13(10):1451–65.
7. Centers for Disease Control and Prevention, (CDC). Licensure of a 13-valent
pneumococcal conjugate vaccine (PCV13) and recommendations for use among
children – Advisory Committee on Immunization Practices (ACIP)
[Internet]. Morbidity and Mortality Weekly Report, 2010 [cited 2014 Sep
13]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/
mm5909a2.htm.
8. Pelton S, Weycker D, Farkouh R, Strutton D, Shea K, Edelsberg J. Risk of
pneumococcal disease in children with chronic medical conditions in the era
of pneumococcal conjugate vaccine. Clin Infect Dis 2014;59(5):615–23.
9. Muhammad RD, Oza-Frank R, Zell E, Link-Gelles R, Narayan KMV, Schaffner W,
et al. Epidemiology of invasive pneumococcal disease among high-risk adults
since the introduction of pneumococcal conjugate vaccine for children. Clin
Infect Dis 2013;56(5):e59–67.
10. Talbot TR, Hartert TV, Mitchel E, Halasa NB, Arbogast PG, Poehling KA, et al.
Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med
2005;352(20):2082–90.
11. Flory JH, Joffe M, Fishman NO, Edelstein PH, Metlay JP. Socioeconomic risk
factors for bacteraemic pneumococcal pneumonia in adults. Epidemiol Infect
2009;137(5):717–26.
12. United States Renal Data System. U.S. Renal Data System 2009 Annual Data
Report: Atlas of chronic kidney disease and end-stage renal disease in the
United States. 2009.
13. Yin Z, Rice BD, Waight P, Miller E, George R, Brown AE, et al. Invasive
pneumococcal disease among HIV-positive individuals 2000-2009. AIDS
2012;26(1):87–94.
14. Payne AB, Link-Gelles R, Azonobi I, Hooper WC, Beall BW, Jorgensen JH, et al.
Invasive pneumococcal disease among children with and without sickle cell
disease in the United States, 1998 to 2009. Pediatr Infect Dis J 2013;32(12):
1308–12.
15. Van Hoek AJ, Andrews N, Waight P, Stowe J, Gates P, George R, et al. The effect of
underlying clinical conditions on the risk of developing invasive pneumococcal
disease in England. J Infect 2012;65(1):17–24.
16. Smith SA, Poland GA. Use of inﬂuenza and pneumococcal vaccines in people
with diabetes. Diabetes Care 2000;23(1):95–108.
17. CELADE – Divisio´n de Poblacio´n de la CEPAL. Estimaciones y proyecciones de
poblacio´n a largo plazo. 1950-2100 – Revisio´n 2013. 2013.18. Chong Neto HJ, Rosa´rio NA, Sole´ D. Asthma and rhinitis in South America: how
different they are from other parts of the world. Allergy Asthma Immunol Res
2012;4(2):62.
19. Sesso RC, Lopes AA, Thome´ FS, Lugon JR, Watanabe Y, Santos DR. Report of the
Brazilian chronic dialysis census. J Bras Nefrol 2012;36(1):48–53.
20. Aschner P. Diabetes trends in Latin America. Diabetes Metab Res Rev 2002;
18(Suppl 3):S27–31.
21. Lervolino LG, Baldin PEA, Picado SM, Calil KB, Viel AA, Campos LAF. Prevalence
of sickle cell disease and sickle cell trait in national neonatal screening studies.
Rev Bras Hematol Hemoter 2011;33(1):49–54.
22. World Health Organization (WHO). Adult HIV prevalence (15–49 years),
2012 by WHO region [Internet]. 2012. Available from: http://www.who.int/
gho/hiv/epidemic_status/prevalence/en/.
23. Organizacio´n Panamericana de la Salud. Informe Regional de SIREVA II, 2012:
datos por paı´s y por grupos de edad sobre las caracterı´sticas de los aislamientos
de Streptococcus pneumoniae, Haemophilus inﬂuenzae y Neisseria meningi-
tidis, en procesos invasores. Washington, DC: OPAS; 2013.
24. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a
9-valent pneumococcal conjugate vaccine in children with and those without
HIV infection. N Eng J Med 2003;349(14):1341–8.
25. Adamkiewicz TV, Silk BJ, Howgate J, Baughman W, Strayhorn G, Sullivan K, et al.
Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with
sickle cell disease in the ﬁrst decade of life. Pediatrics 2008;121(3):562–9.
26. Murray CJL, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al.
Global, regional, and national incidence and mortality for HIV, tuberculosis, and
malaria during 1990-2013: a systematic analysis for the Global Burden of
Disease Study 2013. Lancet 2014;384(14):1005–70.
27. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efﬁcacy of a
pneumococcal conjugate vaccine against acute otitis media. N Eng J Med
2001;344(6):403–9.
28. Centers for Disease Control and Prevention (CDC). Progress in introduction of
pneumococcal conjugate vaccine – worldwide, 2000–2012 [Internet]. Morbid-
ity and Mortality Weekly Report, 2013 [cited 2014 Sep 13]. Available from:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6216a4.htm?s_cid=
mm6216a4_e.
29. Pan American Health Organization (PAHO). Technical Advisory Group on
vaccine - preventable diseases – ﬁnal report. TAG Meeting. Buenos Aires;
2011. p. 49.
30. Repu´blica Dominicana. Incluyen vacuna contra neumococo al programa
ampliado de inmunizacio´n [Internet]. Ministerio de Salud Publica. 2014 [cited
2014 Sep 13]. Available from: http://www.msp.gob.do/article/incluyen-
vacuna-contra-neumococo-al-programa-ampliado-de-inmunizacion.
31. Repu´blica Bolivariana da Venezuela. Vacuna contra el neumococo reducira´ la
mortalidad infantil en Venezuela [Internet]. Ministerio del Poder Popular para
la Comunicacio´n y la Informacio´n. 2014 [cited 2014 Sep 13]. Available from:
http://www.minci.gob.ve/2014/07/vacuna-contra-el-neumococo-reducira-
la-mortalidad-infantil-en-venezuela/.
32. Estado Plurinacional da Bolı´via. Gobierno presenta vacuna ‘‘neumococos’’
[Internet]. 2014 [cited 2014 Sep 13]. Available from: http://www.bolivia.
com/vida-sana/salud/sdi/80475/gobierno-presenta-vacuna-neumococos.
33. Ministe´rio da Sau´de (Brasil). Secretaria de Vigilaˆncia em Sau´de. Departamento
de Vigilaˆncia Epidemiolo´gica. Coordenac¸a˜o-Geral do Programa Nacional de
Imunizac¸o˜es. Proposta para introduc¸a˜o da vacina pneumoco´cica 10-valente
(conjugada) no calenda´rio ba´sico de vacinac¸a˜o da crianc¸a. Brasilia: Ministe´rio
da Sau´de; 2010. 18 p.
34. World Health Organization (WHO). Pneumococcal conjugate vaccine for child-
hood immunization - WHO position paper. Wkly Epidemiol Rec 2007;93–104.
35. Browall S, Backhaus E, Naucler P, Galanis I, Sjo¨stro¨m K, Karlsson D, et al. Clinical
manifestations of invasive pneumococcal disease by vaccine and non-vaccine
types. Eur Respir J 2014;44(6):1646–57.
36. Iroh Tam PY, Madoff LC, Coombes B, Pelton SI. Invasive pneumococcal disease
after implementation of 13-valent conjugate vaccine. Pediatrics 2014;134(2):
210–7.
37. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumo-
coccal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine
for adults with immunocompromising conditions: recommendations of the
Advisory Committee on Immunization Practices (ACIP) [Internet]. Morbidity
and Mortality Weekly Report, 2012 [cited 2014 Sep 13]. Available from: http://
www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm.
38. Tomczyk S, Bennett N, Stoecker C, Gierke R, Moore M, Whitney C, et al. Use of
13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal poly-
saccharide vaccine among adults aged> 65 years: recommendations of the
Advisory Commitee on Immunization Practices (ACIP) [Internet]. Morbidity and
Mortality Weekly Report, 2014 [cited 2014 Dec 15]. p. 822–5. Available from:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6337a4.htm.
39. World Health Organization (WHO). Millennium Development Goals (MDGs).
Health Topics. 2014.
